Saturday 17 October 2026 Export CBIO’s income statement to Excel — free account

Crescent Biopharma, Inc.

Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023. In the quarter to June 2026, revenue grew 1,038,900.0%, EPS grew 85.0% and free cash flow fell 7.04%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.84 0.64 −5.13%

Follow CBIO

Alert me

Market cap: $463.6M
P/E: 0.0×
Fwd P/E: −5.6×
Dividend yield: —
F-score: n/a
Altman Z: −0.06
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 30.61

Total sells 1.51

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	1	—	—	—
Sell	—	—	—	—	—	—	—	7	—	—	7	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 463.56

Revenue 1.22

Net Income (165.12)

Free Cash Flow (71.85)

Net Debt (171.59)

Current Ratio 9.66

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.55)

P/S ratio 296.75

P/B ratio 2.27

Past 5Y EPS Growth —

This Y EPS Growth 78.41%

Next Y EPS Growth (5.24%)

Next Y revenue growth (84.09%)

Next 5Y EPS Growth 37.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 76.00%

10-year low 10-year high

P/B against its own 10 years 55.67%

10-year low 10-year high

EV/Sales against its own 10 years 71.48%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	0.00	0.24
2022	0.00	1.43
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	42	35	213	172
Receivables	—	—	18	—
Inventory	—	—	—	—
Other	—	—	—	—
	44	35	237	179

	2023	2024	2025	Q'26
Payables	1	7	10	3
ST’ Debt	—	—	—	—
Other	—	0	5	5
	7	10	36	19

Compound Annual Growth %

	10y	5y	3y
Sales	—	257.77%	110.67%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	17.50%	9.63%	67.85%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	—	—	—	—
’25	—	—	—	—	11
’23	—	—	—	—	0
’22	—	0	—	—	0
’21	1	0	0	0	1
’20	9	—	1	0	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(19)	—	—	—
’25	(11)	(16)	(18)	(27)	(72)
’24	(11)	(9)	(8)	21	(6)
’23	(12)	(7)	(9)	(8)	(35)
’22	(14)	(16)	(9)	(8)	(46)
’21	(14)	(14)	(17)	(13)	(57)
’20	(4)	(15)	(12)	(10)	(39)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(18)	—	—	—
’25	(11)	(17)	(18)	(27)	(72)
’24	(11)	(9)	(8)	21	(6)
’23	(12)	(7)	(9)	(8)	(35)
’22	(14)	(16)	(9)	(8)	(47)
’21	(14)	(14)	(17)	(13)	(58)
’20	(4)	(15)	(12)	(10)	(39)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.70)	(0.74)	—	—	—
’25	(19.62)	(4.93)	(1.27)	(4.01)	(12.81)
’24	(17.00)	(16.00)	(15.00)	(11.00)	(23.28)
’23	(17.00)	(13.00)	(14.00)	(14.00)	(58.00)
’22	(28.00)	(25.00)	(16.00)	(19.00)	(89.00)
’21	(28.00)	(28.00)	(34.00)	(33.00)	(123.00)
’20	(18.00)	(32.00)	(29.00)	(32.00)	(112.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	370.00	382.00	829.00	264.00	182.00	141.00	51.00	111.00	14.00	9.81	Analyst estimates 2026–2028 Powerpack
	High	925.00	1,825.00	2,605.00	1,356.00	550.00	440.00	319.00	416.00	353.00	37.00
People
People	Employees	42	40	50	57	54	52	39	35	4	44
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.19	0.02	0.00	0.00	0.00	0.25
Income, $m
Income, $m	Revenue	0	—	—	—	10	1	0	0	—	11
	Gross margin, %	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00	—	100.00
	EBT	(32)	(33)	(48)	(58)	(51)	(63)	(47)	(37)	(18)	(152)
	EBT margin, %	(171,944.86)	0.00	0.00	0.00	(502.09)	(5,468.82)	(62,251.73)	(368,994.00)	0.00	(1,401.16)
	Net income	(32)	(33)	(48)	(58)	(51)	(63)	(47)	(37)	(18)	(154)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.09	0.00	0.00	0.00	22.23	2.25	0.14	0.02	0.00	1.04
	Earnings	(150.00)	(113.00)	(118.00)	(134.00)	(112.00)	(123.00)	(89.00)	(58.00)	(23.28)	(12.81)
	Cash flow	(139.85)	(101.25)	(105.56)	(120.17)	(85.83)	(111.74)	(88.44)	(55.07)	(8.17)	(6.87)
	Capex	(3.31)	(1.00)	(0.31)	(0.33)	(0.15)	(0.03)	(0.16)	(0.03)	0.03	(0.09)
	Free cash flow	(143.16)	(102.25)	(105.86)	(120.50)	(85.98)	(111.77)	(88.60)	(55.10)	(8.14)	(6.96)
	Book value	166.04	407.15	500.52	356.45	280.45	158.61	81.72	60.65	(20.17)	19.49
	Shares, m	0	0	0	0	0	1	1	1	1	10
Valuation, ×
Valuation, ×	P/E	0.00	—	—	—	0.00	0.00	0.00	0.00	—	0.00
	P/S	3.80	—	—	—	16.88	63.89	852.55	960.87	—	688.83
	P/B	3.78	—	—	—	1.34	0.91	3.56	4.48	—	0.62
	EV/Sales	2.66	—	—	—	3.61	(13.15)	586.10	729.25	—	(291.15)
	EV/FCF	(3.06)	—	—	—	(0.94)	0.27	(2.26)	(3.75)	—	0.72
Cash, $m
Cash, $m	Operating cash flow	(30)	(30)	(43)	(52)	(39)	(57)	(46)	(35)	(6)	(72)
	Capex	(1)	0	0	0	0	0	0	0	0	(1)
	Free cash flow	(30)	(30)	(43)	(52)	(39)	(58)	(47)	(35)	(6)	(72)
Balance, $m
Balance, $m	Working capital	34	119	204	152	126	79	42	37	25	201
	Total debt	—	—	—	3	2	1	1	—	37	—
	Net debt	(40)	(124)	(210)	(155)	(135)	(89)	(48)	(42)	3	(213)
	Shareholders’ equity	35	120	205	154	128	82	43	38	(15)	203
Returns, %
Returns, %	ROA	(70.03)	(38.93)	(28.11)	(30.25)	(32.84)	(53.48)	(63.89)	(75.98)	(44.15)	(111.59)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(83.96)	(42.94)	(29.69)	(32.19)	(36.14)	(60.46)	(74.98)	(90.72)	(155.80)	(167.75)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NGNE Neurogene Inc.	$479.3M	— (loss-making)	— (loss-making)	—	n/m	−22.97% (below 0%: shrinking)	100.00%	0.00%	Compare
YDES YD Bio Limited	$477.5M	—	—	—	—	—	—	—	Compare
RGNX REGENXBIO Inc.	$472.7M	— (loss-making)	— (loss-making)	+405.73% (above 0%: growing)	n/m	−26.67% (below 0%: shrinking)	99.04%	27.09%	Compare
ARVN Arvinas, Inc.	$468.2M	53.6×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
CBIO Crescent Biopharma, Inc.	$463.6M	— (loss-making)	— (loss-making)	+1,038,900.00% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	100.00%	0.00%
ALLO Allogene Therapeutics, Inc.	$463.0M	— (loss-making)	— (loss-making)	+20,990.91% (above 0%: growing)	n/m	+17.73% (above 0%: growing)	100.00%	(1,011.21%)	Compare
ALT Altimmune, Inc.	$459.1M	— (loss-making)	— (loss-making)	+520.00% (above 0%: growing)	n/m	−25.27% (below 0%: shrinking)	100.00%	0.00%	Compare
AUTL Autolus Therapeutics PLC Sponsored ADR	$457.8M	— (loss-making)	— (loss-making)	+118.37% (above 0%: growing)	n/m	+67.55% (above 0%: growing)	55.20%	(95.95%)	Compare
OCS Oculis Holding AG	$456.8M	— (loss-making)	— (loss-making)	+23.96% (above 0%: growing)	n/m	−10.40% (below 0%: shrinking)	100.00%	(7,603.42%)	Compare
Median of peers	$465.6M	—	—	+462.87%	—	−10.40%	100.00%	0.00%

All 614 Biotechnology stocks →

Crescent Biopharma, Inc. (CBIO) key facts

Strength: Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023.
Crescent Biopharma, Inc. (CBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CBIO traded at $11.84, a market capitalization of $463.6 million.
Return on equity was −167.8% and debt-to-equity 0.00.
Its Altman Z-score is −0.06 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.